Alzheimer’s disease: clinical management errors

The management of patients with Alzheimer’s disease (AD) is one of the urgent problems of modern medicine, however, not only general practitioners, but also neurologists in our country are not sufficiently aware of modern methods of AD therapy, which largely determines the errors in patient management. The disease is rarely diagnosed, patients are often observed with an erroneous diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia, discirculatory encephalopathy) and do not receive the necessary treatment. It is relatively rare for AD patients to receive advice on non-drug therapies that include cognitive stimulation, cognitive training, regular physical activity, and antioxidant-rich nutrition. Anti dementic agents are rarely prescribed to patients: acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine, an NMDA receptor blocker. Only a relatively small percentage of people who developed Alzheimer’s disease receive effective antidement therapy. This may be due to the fact that AD is not diagnosed or is diagnosed at more advanced stages of the disease when antidement therapy is not so effective, or that doctors do not have sufficient knowledge about antidement drugs and, finally, that the price of drugs is relatively high and the prescribing process for preferential provision of drugs is rather complicated. Unfortunately, antipsychotics and benzodiazepines are often unreasonably prescribed to patients with AD, the use of which impairs cognitive functions. The article presents a clinical observation of a relatively young patient with AD, who was followed up for a long time with an erroneous diagnosis of discirculatory encephalopathy. The issues of optimizing the management of AD patients in our country are discussed, and the data of the Cochrane review on the use of donepezil at different stages of the disease are analyzed.

1. Chertkow H., Feldman H.H., Jacova C., Massoud F. Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013;5(Suppl. 1):S2. doi: 10.1186/alzrt198.

2. Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007.

3. Mansfield E., Noble N., Sanson-Fisher R., Mazza D., Bryant J. Primary Care Physicians’ Perceived Barriers to Optimal Dementia Care: A Systematic Review. Gerontologist. 2019;59(6):e697-e708. doi: 10.1093/geront/gny067.

4. Neverovsky D.V., Sluchevskaya S.F., Parfenov V.A. Differential diagnosis of dyscirculatory encephalopathy in outpatient practice. Nevrologiya, neyrop-sikhiatriya i psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):38-42. (In Russ.) doi: 10.14412/2074-2711-2013-2411.

5. Parfenov V.A., Zakharov V.V., Preobrazhenskaya I.S. Cognitive Disorders. Moscow: Remedium; 2014. 224 p. (In Russ.)

6. Koberskaya N.N. Alzheimer’s disease. Nevrologiya, neyropsikhiatriya i psik-hosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):52-60. (In Russ.) doi: 10.14412/2074-2711-2019-3S-52-60.

7. Sevigny J., Chiao R, Bussiere T., Weinreb P.H., Williams L., Maier M. et al. The antibody aducanumab reduces Ав plaques in Alzheimer’s disease. Nature. 2016;537(7618):50-56. doi: 10.1038/nature19323.

8. Tolar M., Abushakra S., Hey J.A., Porsteinsson A., Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801 - the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95. doi: 10.1186/s13195-020-00663-w.

9. Eriksson H., Fereshtehnejad S.M., Falahati F., Farahmand B., Religa D., Eriksdotter M. Differences in routine clinical practice between early and late onset Alzheimer’s disease: data from the Swedish Dementia Registry (SveDem). J Alzheimers Dis. 2014;41(2):411-419. doi: 10.3233/JAD-132273.

10. Gong L., Liu X.Y., Fang M. Recent progress on small vessel disease with cognitive impairment. Int J Clin Exp Med. 2015;8(5):7701-7709. Available at: https//www.ncbi.nlm.nih.gov/pmc/articles/PMC4509265.

11. Xie B., Shi X., Xing Y, Tang Y Association between atherosclerosis and Alzheimer’s disease: A systematic review and meta-analysis. Brain Behav. 2020;10(4):e01601. doi: https://doi.org/10.1002/brb3.1601.

12. Kales H., Gitlin L., Lyketsos C. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762-769. doi: 10.1111/jgs.12730.

13. Cocchiara R.A., De Lucia F., Koci L., Lisanti E., Petruccini G., La Torre G. Management of the early stage of Alzheimer’s disease: a systematic review of literature over the past 10 years. Clin Ter. 2020;171(4):e357-e368. doi: 10.7417/CT.2020.2239.

14. Bahar-Fuchs A., Clare L., Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2013;(6):CD003260. doi: 10.1002/14651858.CD003260.pub2.

15. Chalfont G., Milligan C., Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020;19(4):1086-1130. doi: 10.1177/1471301218795289.

16. Groot C., Hooghiemstra A.M., Raijmakers P.G., van Berckel B.N., Scheltens R, Scherder EJ. et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev. 2016;25:13-23. doi: 10.1016/j.arr.2015.11.005.

17. Colcombe S., Kramer A.F. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol Sci. 2003;14(2):125-130. doi: 10.1111/1467-9280.t01-1-01430.

18. van den Brink A.C., Brouwer-Brolsma E.M., Berendsen AA.M., van de Rest O. The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer’s Disease-A Review. Adv Nutr. 2019;10(6):1040-1065. doi: 10.1093/advances/nmz054.

19. Qaseem A., Snow V., Cross J.TJr., Forciea M.A., Hopkins R., Shekelle P. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-378. doi: 10.7326/00034819-148-5-200803040-00008.

20. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. doi: 10.1002/14651858.CD005593.

21. Birks J.S., Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.

22. Winblad B., Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135-146. doi: 10.1002/(sici)1099-1166(199902)14:2<135::aid-gps906>3.0.co;2-0.

23. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333-1341. doi: 10.1056/NEJMoa013128.

24. van Dyck C.H., Schmitt F.A., Olin J.T. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006;14(5):428-437. doi: 10.1097/01.JGR0000203151.17311.38.

25. Kales H., Kim H., Zivin K., Valenstein M., Seyfried L.S., Chiang C. et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79. doi: 10.1176/appi.ajp.2011.11030347.

26. Sychev D.A., Zhuchkov A.V., Tereshchenko O.V., Ivashchenko D.V. Tapering (deprescribing) of benzodiazepine tranquilizers. Nevrologiya, neyropsikhiatriya i psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):89-95. (In Russ.) doi: 10.14412/2074-27112019-1-89-95.

27. Reus V., Fochtmann L., Eyler A., Hilty D.M., Horvitz-Lennon M., Jibson M.D. et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. doi: 10.1176/appi.ajp.2015.173501.

28. Ettcheto M., Olloquequi J., Sanchez-Lopez E., Busquets O., Cano A., Manzine P.R. et al. Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer’s Disease Dementia. Front Aging Neurosci. 2020;11:344. doi: 10.3389/fnagi.2019.00344.

29. Patterson C., Feightner J.W., Garcia A., Hsiung G.Y, MacKnight C., Sadovnick A.D. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178(5):548-556. doi: 10.1503/cmaj.070796.